Improving natural killer cell cancer immunotherapy

被引:36
作者
Berrien-Elliott, Melissa M. [1 ]
Romee, Rizwan [1 ]
Fehniger, Todd A. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
关键词
cancer; immunotherapy; natural killer cells; ACUTE MYELOID-LEUKEMIA; CHIMERIC ANTIGEN RECEPTOR; RELAPSED/REFRACTORY MULTIPLE-MYELOMA; ACUTE MYELOGENOUS LEUKEMIA; KIR ANTIBODY IPH2101; NK CELLS; T-CELLS; CYTOKINE PRODUCTION; PHASE-1; TRIAL; TUMOR-CELLS;
D O I
10.1097/MOT.0000000000000243
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Purpose of review Natural killer (NK) cells are innate lymphoid cells specialized to eliminate malignant cells via direct cytotoxicity and immunoregulatory cytokine production. As such, NK cells are ideal as cellular therapy for cancer patients, and several studies have provided proof of principle that adoptively transferred NK cells can induce remissions in patients with leukemia. A clear understanding of the mechanisms underlying NK cell antitumor responses, including target cell recognition, activation status, and negative regulatory signals will improve NK cellular therapy for cancer patients. Recent findings Clinical studies have demonstrated the safety and preliminary efficacy of NK cell adoptive transfer, especially in hematologic malignancies. Various NK cell sources, isolation techniques, activation approaches, and ex-vivo expansion strategies are under investigation. New approaches have been developed and are being tested to optimize NK cell therapy, including ways to better target NK cells to malignant cells, increase their functional competence, facilitate expansion in patients, and limit inhibitory signals or cells. Summary NK cells represent a promising cellular immunotherapy for the treatment of cancer. In addition to adoptive cellular therapy, adjunct treatments that optimize NK cell targeting and function will enhance their potency and broaden their potential use to many cancer types.
引用
收藏
页码:671 / 680
页数:10
相关论文
共 77 条
[1]   Differential activation of cord blood and peripheral blood natural killer cells by cytokines [J].
Alnabhan, Rehab ;
Madrigal, Alejandro ;
Saudemont, Aurore .
CYTOTHERAPY, 2015, 17 (01) :73-85
[2]   Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein [J].
Bachanova, Veronika ;
Cooley, Sarah ;
Defor, Todd E. ;
Verneris, Michael R. ;
Zhang, Bin ;
McKenna, David H. ;
Curtsinger, Julie ;
Panoskaltsis-Mortari, Angela ;
Lewis, Dixie ;
Hippen, Keli ;
McGlave, Philip ;
Weisdorf, Daniel J. ;
Blazar, Bruce R. ;
Miller, Jeffrey S. .
BLOOD, 2014, 123 (25) :3855-3863
[3]   Allogeneic natural killer cells for refractory lymphoma [J].
Bachanova, Veronika ;
Burns, Linda J. ;
McKenna, David H. ;
Curtsinger, Julie ;
Panoskaltsis-Mortari, Angela ;
Lindgren, Bruce R. ;
Cooley, Sarah ;
Weisdorf, Daniel ;
Miller, Jeffrey S. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (11) :1739-1744
[4]   A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma [J].
Benson, Don M., Jr. ;
Cohen, Adam D. ;
Jagannath, Sundar ;
Munshi, Nikhil C. ;
Spitzer, Gary ;
Hofmeister, Craig C. ;
Efebera, Yvonne A. ;
Andre, Pascale ;
Zerbib, Robert ;
Caligiuri, Michael A. .
CLINICAL CANCER RESEARCH, 2015, 21 (18) :4055-4061
[5]   A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].
Benson, Don M., Jr. ;
Hofmeister, Craig C. ;
Padmanabhan, Swaminathan ;
Suvannasankha, Attaya ;
Jagannath, Sundar ;
Abonour, Rafat ;
Bakan, Courtney ;
Andre, Pascale ;
Efebera, Yvonne ;
Tiollier, Jerome ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2012, 120 (22) :4324-4333
[6]  
Berrien-Elliott M.M., 2015, J INNATE IMMUN
[7]   Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells [J].
Boyerinas, Benjamin ;
Jochems, Caroline ;
Fantini, Massimo ;
Heery, Christopher R. ;
Gulley, James L. ;
Tsang, Kwong Yok ;
Schlom, Jeffrey .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) :1148-1157
[8]   Human natural killer cells [J].
Caligiuri, Michael A. .
BLOOD, 2008, 112 (03) :461-469
[9]   Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome [J].
Chamuleau, MED ;
Souwer, Y ;
van Ham, SM ;
Zevenbergen, A ;
Westers, TM ;
Berkhof, J ;
Meijer, CJLM ;
van de Loosdrecht, AA ;
Ossenkoppele, GJ .
CANCER RESEARCH, 2004, 64 (16) :5546-5550
[10]   Bringing natural killer cells to the clinic: ex vivo manipulation [J].
Childs, Richard W. ;
Berg, Maria .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, :234-246